Adjuvant Capital — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Curevo Vaccinecurevovaccine.cominMar 2025 · $110M
Curevo Vaccine is a clinical-stage biotech company developing non-mRNA vaccines, with a lead adjuvanted subunit vaccine candidate (amezosvatein/CRV-101) for shingles and chickenpox.
BiotechHealthtech
Co-investorsOrbiMedRA CapitalSanofi VenturesHBM Healthcare InvestmentsJanus Henderson InvestorsMedicxi
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.